Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

Ocular Therapeutix announced the company’s conference participation in the upcoming annual OIS Retina Innovation Summit, the American Society of Retina Specialists (ASRS), and Women in Ophthalmology ...

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

Advertorial: Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy? The triad of inflammation, neuropathy, and vasculopathy plays a key role ...

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Atsena Therapeutics expands its ATSN-201 trial for X-linked retinoschisis, a step toward the first gene therapy treatment.

Belite Bio completes enrollment in the pivotal PHOENIX trial, advancing tinlarebant's potential to treat geographic atrophy.

Nanoscope Therapeutics establishes a Vision Advisory Committee to enhance retinal care and drive innovative therapies for vision restoration.